Claims
- 1. A composition suitable for the delivery of an active ingredient comprising monolayer vesicles of about 30 to about 200 nanometers in a pharmaceutically acceptable carrier, the vesicles comprising an active ingredient in mixture with a triglyceride selected from the group consisting of trimyristoylglycerol and trilauroylglycerol, and an encapsulating consisting of a monolayer which comprises a phospholipid material.
- 2. The composition of claim 1 wherein the encapsulating layer includes cholesterol.
- 3. The composition of claim 1 wherein the active ingredient is substantially aqueous-insoluble.
- 4. The composition of claim 1 wherein the phospholipid material is selected from the group of phospholipids having alkyl side chains of from 12 to 20 carbons in length.
- 5. The composition of claim 4 wherein the phospholipid material includes an anionic phospholipid component.
- 6. The composition of claim 1 wherein the phospholipid material comprises a mixture of dialkoylphosphatidylcholine and dialkoylphosphatidylglycerol compounds having alkyl side chains of from 12 to 20 carbons in length.
- 7. The composition of claim 6 wherein the encapsulating layer includes distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol.
- 8. The composition of claim 1 wherein the carrier is an aqueous saline solution, an aqueous monosaccharide solution or an aqueous disaccharide solution.
- 9. The composition of claim 1 wherein the carrier includes glycerol.
- 10. A composition suitable for the delivery of a hexamethylmelamine active ingredient comprising monolayer vesicles of about 30 to about 200 nanometers in a pharmaceutically acceptable carrier, the vesicles comprising hexamethylmelamine in mixture with a triglyceride selected from the group consisting of trimyristoylglycerol and trilauroylglycerol, and an encapsulating layer consisting of a monolayer which comprises a phospholipid material.
- 11. The composition of claim 10 wherein the phospholipid material includes an anionic phospholipid component.
- 12. The composition of claim 10 wherein the phospholipid material comprises a mixture of dialkoylphosphatidylcholine and dialkoylphosphatidylglycerol compounds having from 12 to 20 carbons in length.
- 13. The composition of claim 12 wherein the encapsulating layer includes distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol.
- 14. The composition of claim 10 wherein the carrier includes glycerol and is an aqueous saline solution, an aqueous monosaccharide solution or an aqueous disaccharide solution.
- 15. A method for treating neoplastic tumors in a human body comprising parenterally administering multiple doses of the composition claimed in claims 1 or 10.
- 16. The method of claim 15 wherein the administration is by intravenous injection.
- 17. A method of making a composition suitable for the delivery of an active ingredient comprising the steps of:
- (1) solubilizing an active ingredient with a mixture consisting essentially of a triglyceride selected from the group consisting of trimyristoylglycerol and trilauroylglycerol, a phospholipid material and a pharmaceutically acceptable carrier;
- (2) forming vesicles containing the active ingredient; and
- (3) removing undesirable materials from the resulting composition, wherein said vesicles are monolayer vesicles comprising an encapsulating monolayer of phospholipid material.
- 18. The method of claim 17 wherein said vesicles have a size of about 30 to about 200 nanometers.
Parent Case Info
This application is a continuation of application Ser. No. 7,338, filed Jan. 27, 1987 and now abandoned.
US Referenced Citations (9)
Continuations (1)
|
Number |
Date |
Country |
Parent |
7338 |
Jan 1987 |
|